What’s going on?
Pfizer counted 170 cases of coronavirus infection among volunteers who participated in the trial stage.
- The company said there were 162 infections for those who got the placebo, or plain saline shots, while there were eight for those who got the vaccine.
- Pfizer said that means there’s a 95% efficacy rate.
- Pfizer said there were also 10 severe cases of COVID-19 in the trial. Nine cases came from the placebo group and only one came from the vaccinated group.
- The name of the vaccine is BNT162b2.
- “Efficacy was consistent across age, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%,” said Pfizer and its German partner, BioNTech, said in a joint statement.
Pfizer and BioNTech said last week that the coronavirus vaccine was 90% effective, which I wrote about for the Deseret News. The analysis reviewed 94 confirmed cases among 43,000 participants in the vaccine trial.
- “The rapid protection this vaccine provides — combined with its tolerability profile in all age groups studied so far — should help make this vaccine an important tool to address the current pandemic,” said Dr. Ugur Sahin, CEO and co-founder of BioNTech.